Mode
Text Size
Log in / Sign up
Phase 3 N=165 Randomized Treatment

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Enrolled (actual)
165
Serious AEs
30.2%
Results posted
Sep 2025
Primary outcome: Primary: Participants >=2 Years of Age: Observed Steady-State Trough (Pre-dose) Plasma Concentration of Macitentan and Aprocitentan (Active Metabolite) at Week 12 Based on Body Weight — 150.133; 153.892; 200.975; 208.067 nanograms per milliliter (ng/mL)

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Macitentan (Drug); Standard-of-care (Other)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
Actelion
Primary completion
Aug 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Participants >=2 Years of Age: Observed Steady-State Trough (Pre-dose) Plasma Concentration of Macitentan and Aprocitentan (Active Metabolite) at Week 12 Based on Body Weight
150.133; 153.892; 200.975; 208.067; 1165.000; 859.333
PRIMARY
Participants >=2 Years of Age: Observed Steady-State Trough (Pre-dose) Plasma Concentration of Macitentan and Aprocitentan (Active Metabolite) at Week 12 Based on Age Group
159.767; 184.792; 196.484; 1063.333; 957.211; 970.842
PRIMARY
Participants <2 Years of Age: Observed Steady-State Trough (Pre-dose) Plasma Concentration of Macitentan and Aprocitentan (Active Metabolite) at Week 4
101.822; 707.089
PRIMARY
Participants From China With >=12 to <18 Years of Age: Observed Steady-State Trough (Pre-dose) Plasma Concentration of Macitentan and Aprocitentan (Active Metabolite) at Week 12
201.61; 1313.75
SECONDARY
Time to the First Clinical Event Committee (CEC)-Confirmed Disease Progression Event
SECONDARY
Time to First CEC-confirmed Hospitalization for PAH
SECONDARY
Time to CEC-confirmed Death Due to PAH
SECONDARY
Time to Death (All Causes)
SECONDARY
Percentage of Participants With World Health Organization (WHO) Functional Class (FC) I or II Versus III or IV
SECONDARY
Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Weeks 12 and 24
SECONDARY
Change From Baseline in Mean Daily Time Spent in Moderate to Vigorous Physical Activity as Measured by Accelerometry at Week 48
SECONDARY
Change From Baseline in Body Surface Area (BSA) Normalized Tricuspid Annular Plane Systolic Excursion (TAPSE) Measured by Echocardiography at Week 24
SECONDARY
Change From Baseline in Left Ventricular Eccentricity Index (LVEI) Measured by Echocardiography at Week 24
SECONDARY
Change From Baseline in Quality of Life Measured by Pediatric Quality of Life Inventory Version 4.0 (PedsQL 4.0) Generic Core Scales Short Form (SF-15)
SECONDARY
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
SECONDARY
Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
SECONDARY
Number of Participants With AEs Leading to Premature Discontinuation of Macitentan or Standard of Care (SoC)
SECONDARY
Number of Participants With AEs of Special Interest
SECONDARY
Number of Participants With Marked Laboratory Abnormalities
SECONDARY
Change From Baseline in Selected Laboratory Parameters
SECONDARY
Change From Baseline in Vital Signs (Blood Pressure, Heart Rate)
SECONDARY
Change From Baseline in Growth Variable
SECONDARY
Change From Baseline in Sexual Maturation Measured by Tanner Stage

Summary

This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to evaluate pharmacokinetics (PK), safety and efficacy of macitentan in children with pulmonary arterial hypertension (PAH).

Eligibility Criteria

Key Inclusion Criteria

  • Signed informed consent by the parent(s) or legally designated representative and assent from developmentally capable children prior to initiation of any study-mandated procedure
  • Males or females between greater than or equal to (>=) 1 month and less than ( = 3.5 kilograms (kg) at randomization
  • Pulmonary arterial hypertension (PAH) diagnosis confirmed by historical RHC (mPAP greater than or equal to [>=] 25 millimeters of mercury [mmHg], and Pulmonary artery wedge pressure [PAWP] less than or equal to [ ] 3 WU × m2), where in the absence of pulmonary vein obstruction and/or significant lung disease PAWP can be replaced by Left atrium pressure [LAP] or Left ventricular end diastolic pressure [LVEDP] (in absence of mitral stenosis) assessed by heart catheterization
  • PAH belonging to the Nice 2013 Updated Classification Group 1 (including participants with Down Syndrome) and of following etiologies: idiopathic PAH; heritable PAH; PAH associated with congenital heart disease (CHD); Drug or toxin induced PAH; PAH associated with HIV; PAH associated with connective tissue diseases (PAH-aCTD); and World health organization (WHO) Functional class I to III
  • Females of childbearing potential must have a negative pregnancy test at Screening and at Baseline, and must agree to undertake monthly pregnancy tests, and to use a reliable method of contraception (if sexually active) up to the end of study (EOS)

Key Exclusion Criteria

  • Participants with PAH due to portal hypertension, schistosomiasis, or with pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis, and persistent pulmonary hypertension of the newborn
  • Participants with PAH associated with Eisenmenger syndrome, or with moderate to large left-to-right shunts
  • Participants receiving a combination of > 2 PAH-specific treatments at randomization.
  • Treatment with intravenous (IV) or subcutaneous (SC) prostanoids within 4 weeks before randomization, unless given for vasoreactivity testing
  • Hemoglobin or hematocrit ) 3 times the upper limit of normal range
  • Pregnancy (including family planning) or breastfeeding.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol
  • Severe hepatic impairment, for example Child-Pugh Class C
  • Clinical signs of hypotension which in the investigator's judgment would preclude initiation of a PAH-specific therapy
  • Severe renal insufficiency (estimated creatinine clearance 221 micro-moles per liter [micro-mol/L])
  • Participants with known diagnosis of bronchopulmonary dysplasia
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02932410). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search